Kevin Hughes

Kevin Hughes

Auto-generated profile, based on publicly available information

Kevin Hughes

IPEC (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SSSmita Salunke
Smita Salunke
DCDavid Clapham
David Clapham
AAAnjali Agrawal
Anjali Agrawal
KHKevin Hughes
Kevin Hughes
TNTony Nunn
Tony Nunn

17 August 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SSSmita Salunke
Smita Salunke
AAAnjali Agrawal
Anjali Agrawal
JWJennifer Walsh
Jennifer Walsh
ANAnthony Nunn
Anthony Nunn
KHKevin Hughes
Kevin Hughes
PSPhilip Sherratt
Philip Sherratt

8 August 2024 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
AAAnjali Agrawal
Anjali Agrawal
SSSmita Salunke
Smita Salunke
ARAlfred Rumondor
Alfred Rumondor
KTKaren Thompson
Karen Thompson
GCGrazia Caivano
Grazia Caivano
PKPeter Kuehl
Peter Kuehl
It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The "Paediatric Excipient Risk Assessment (PERA)" framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products. This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool's usefulness.